A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

Start Date27 Jul 2023

Sponsor / Collaborator

Altimmune, Inc.

NCT05295875

/ CompletedPhase 2

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Start Date31 Mar 2022

Sponsor / Collaborator

Altimmune, Inc.

NCT05292911

/ CompletedPhase 1

A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).

Start Date09 Mar 2022

Sponsor / Collaborator

Altimmune, Inc.

100 Clinical Results associated with Pemvidutide

100 Translational Medicine associated with Pemvidutide

100 Patents (Medical) associated with Pemvidutide

Literatures (Medical) associated with Pemvidutide

01 May 2025·PEPTIDES

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Review

Author: Flatt, Peter R ; Bailey, Clifford J ; Conlon, J Michael

Recent studies with peptide-based incretin therapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the dual agonist tirzepatide that engages receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials and 'real-world' studies have confirmed the marked glucose-lowering and weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young and elderly individuals with and without diabetes and/or overweight or obesity. Recent studies have also confirmed protections against the development and progression of cardiovascular and renal diseases that are additive to the benefits conferred by improved control of blood glucose and body weight. Emerging evidence suggests that incretin therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea and possibly degenerative bone disorders and cognitive decline. New incretin-based peptide therapies in development include a long-acting glucagon receptor agonist (LY3324954), dual GLP-1/glucagon receptor agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon receptor agonists (retatrutide, efocipegtrutide), a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), a unimolecular GLP-1/amylin receptor dual agonist (amycretin), and a GIP receptor antibody with GLP-1 receptor agonism (MariTide). The creation of multi-targeting incretin-based synthetic peptides provides opportunities for improved management of type 2 diabetes and obesity as well as new therapeutic approaches to an expanding list of associated co-morbidities. The aim of the review is to acquaint the reader with developments in the field from 2023 to the present (February 2025).

01 Feb 2025·Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL – 2024

Review

Author: Khaitovych, Mykola V. ; Pinsky, Leonid L. ; Ryzhova, Irina P. ; Golubovska, Olga A.

Aim: To systematize and comprehensively analyze scientific sources and studies on metabolic-associated steatotic liver disease (MASLD) based on materials from the European Congress of the European Association for the Study of the Liver (EASL – 2024). Materials and Methods: This paper analyzes the current scientific research on the prevalence, pathogenesis, diagnostic methods, prognosis, and pharmacotherapy of MASLD presented at the EASL 2024 Congress. The following methods were used in the preparation of the work: a systematic approach and bibliosemantic analysis. Conclusions: Studies on the pathogenesis of MASLD progression confirm the significant role of insulin resistance and hyperinsulinemia in increasing hepatocyte cytolysis activity, raising the concentration of cytokeratin CK-18, HbA1c, low-density lipoproteins, triglycerides, and the severity of fibrosis (FIB-4). EASL 2024 studies evaluated the diagnostic efficiency of non-invasive methods for assessing steatosis and liver fibrosis severity in MASLD (FIB-4, FibroScan®, Enhanced Liver Fibrosis (ELF), Vibration Controlled Transient Elastography (VCTE), LiverPRO, etc.). Due to the high prevalence of steatotic liver disease, comorbidities such as chronic viral hepatitis C, autoimmune hepatitis, and alcoholic liver disease – contributing to liver fibrosis progression and hepatocellular carcinoma – are significant. Promising drugs for MASLD treatment include resmethyrom, fibroblast growth factor 21 analogs (including pegosafermin), and pemvidutide, a long-acting, balanced GLP-1/glucagon dual receptor agonist.

01 Jan 2025·JOURNAL OF HEPATOLOGY

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

Article

Author: Browne, Sarah K ; Harrison, Stephen A ; Gutierrez, Julio A ; Roberts, M Scot ; Suschak, John J ; Harris, M Scott ; Yang, Jay ; Tomah, Shaheen

BACKGROUND & AIMS:

This was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

METHODS:

Patients with a BMI ≥28.0 kg/m² and LFC ≥10% by magnetic resonance imaging-proton density fat fraction were randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo administered subcutaneously once weekly for 12 weeks. Participants were stratified according to a diagnosis of type 2 diabetes mellitus. The primary efficacy endpoint was relative reduction (%) from baseline in LFC after 12 weeks of treatment.

RESULTS:

Ninety-four patients were randomized and dosed. Median baseline BMI and LFC across the study population were 36.2 kg/m² and 20.6%; 29% of patients had type 2 diabetes mellitus. At week 12, relative reductions in LFC from baseline were 46.6% (95% CI -63.7 to -29.6), 68.5% (95% CI -84.4 to -52.5), and 57.1% (95% CI -76.1 to -38.1) for the pemvidutide 1.2 mg, 1.8 mg, and 2.4 mg groups, respectively, vs. 4.4% (95% CI -20.2 to 11.3) for the placebo group (p <0.001 vs. placebo, all treatment groups), with 94.4% and 72.2% of patients achieving 30% and 50% reductions in LFC and 55.6% achieving normalization (≤5% LFC) at the 1.8 mg dose. Maximal responses for weight loss (-4.3%; p <0.001), alanine aminotransferase (-13.8 IU/L; p = 0.029), and corrected cT1 (-75.9 ms; p = 0.002) were all observed at the 1.8 mg dose. Pemvidutide was well-tolerated at all doses with no severe or serious adverse events.

CONCLUSIONS:

In patients with MASLD, weekly pemvidutide treatment yielded significant reductions in LFC, markers of hepatic inflammation, and body weight compared to placebo.

IMPACT AND IMPLICATIONS:

Metabolic dysfunction-associated steatotic liver disease, and its progressive form steatohepatitis, are strongly associated with overweight/obesity and it is believed that the excess liver fat associated with obesity is an important driver of these diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists elicit weight loss through centrally and peripherally mediated effects on appetite. Unlike GLP-1R agonists, glucagon receptor agonists act directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis, potentially providing a more potent mechanism for liver fat content reduction than weight loss alone. This study demonstrated the ability of once-weekly treatment with pemvidutide, a dual GLP-1R/glucagon receptor agonist, to significantly reduce liver fat content, hepatic inflammatory activity, and body weight, suggesting that pemvidutide may be an effective treatment for both metabolic dysfunction-associated steatohepatitis and obesity.

CLINICAL TRIAL NUMBER:

NCT05006885.

123

News (Medical) associated with Pemvidutide

13 May 2025

·ir.altimmune.com

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company’s pemvidutide development plans and financing needs. Access to this additional capital strengthens Altimmune’s balance sheet, which included $150 million in cash and cash equivalents as of March 31, 2025, and will support the ongoing development of pemvidutide, Altimmune’s novel GLP-1/glucagon dual receptor agonist. Pemvidutide is currently being studied in IMPACT, a Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH), with top-line data expected in Q2 2025. In addition, Phase 2 trials evaluating pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) are expected to be initiated in the second and third quarters of 2025, respectively. Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune said, “We are excited to partner with Hercules, which has a strong history of funding innovative biopharmaceutical companies. We look forward to working with the Hercules team to maximize the potential of pemvidutide in liver and cardiometabolic indications. With our existing cash on hand, we expect this credit facility to significantly extend our cash runway at flexible, attractive terms.” “Hercules is thrilled to support Altimmune as it develops pemvidutide as a potential therapy for the treatment of MASH, AUD and ALD,” said Adam Soller, Managing Director at Hercules Capital. “We look forward to the upcoming data release from the IMPACT trial and serving as a long-term capital partner to Altimmune through its next chapter of clinical development.” Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune’s option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke, Biotech Phone: 619-849-5383 jake.robison@inizioevoke.com This press release was published by a CLEAR® Verified individual. Source: Altimmune, Inc

Phase 2

08 May 2025

·ir.altimmune.com

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress™ in Amsterdam, The Netherlands. The presentation focuses on the use of the MASH Resolution Index (MASHResInd) algorithm to predict MASH resolution on biopsy in patients treated with pemvidutide, Altimmune’s 1:1 GLP-1/glucagon dual receptor agonist. Developed by Dr. Rohit Loomba, Professor of Medicine, Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California San Diego, MASHResInd is a composite score incorporating multiple non-invasive tests, including MRI proton-density-fat-fraction (MRI-PDFF), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels for predicting MASH resolution on biopsy. Applied to datasets from a previously completed trial with pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD), the MASHResInd predicted a high probability that MASH resolution would occur with pemvidutide treatment. “These findings underscore the potential of pemvidutide to achieve meaningful histologic improvements in MASH using non-invasive, reproducible biomarkers,” said Dr. Loomba. “We are encouraged by the significant response in the MASHResInd model, which may suggest a high likelihood of achieving MASH resolution in Altimmune’s IMPACT Phase 2b Trial of pemvidutide.” Key Data Highlights: The composite MASHResInd score is a robust, non-invasive marker for liver histology improvement, with potential application across clinical research and practice. In the analyses presented at EASL, 24 weeks of treatment with pemvidutide resulted in MASHResInd responses (defined as an index ≥ -0.67) in 69.2%, 92.3% and 90.9% of subjects receiving 1.2 mg (p<0.05), 1.8 mg (p<0.001), and 2.4 mg (p<0.001) of pemvidutide, respectively, compared with 22.2% in subjects receiving placebo. “This analysis of patients from our study of pemvidutide in MASLD further reinforces our excitement around the upcoming IMPACT readout, which remains on track to be reported this quarter,” added Scott Harris, M.D., Chief Medical Officer of Altimmune. “Our MASLD trial achieved class-leading reductions in liver fat content, which is recognized to be a primary driver for MASH resolution and fibrosis improvement. The MASHResInd response rates greater than 90% at the 1.8 and 2.4 mg pemvidutide doses give us further confidence in the ability of pemvidutide to achieve statistical significance in the 24-week biopsy-based endpoints of the IMPACT Trial.” Presentation Details Session: MASLD: Therapy, Track Hub 7 – Metabolism, Alcohol, and Toxicity (Poster# SAT-453) Date/Time: Thursday, May 8, 2025, at 9:45 am CET Session: MASLD Therapy Section (Poster# SAT-453) Date/Time: Saturday, May 10, 2025, from 12:00 PM to 1:00 PM CET The posters presented at the EASL International Liver Congress™ 2025 will be accessible on the Events section of the Altimmune website. About Pemvidutide Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of obesity, MASH, alcohol use disorder (AUD) as well as alcohol liver disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial. IND applications in AUD and ALD have received FDA clearance with Phase 2 trials to commence in mid-2025. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke Comms Phone: 619-849-5383 Jake.robison@inizioevoke.com This press release was published by a CLEAR® Verified individual. Source: Altimmune, Inc

Phase 2Clinical ResultFast Track

01 May 2025

·ir.altimmune.com

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index (MASHResInd; Loomba 2024), a highly sensitive non-invasive measure of MASH histologic response, in a poster session at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2025 in Amsterdam, The Netherlands. The abstract will be featured in the conference poster session and poster tour. Details of the presentations are as follows: Session: MASLD: Therapy, Track Hub 7 – Metabolism, Alcohol, and Toxicity (Poster# SAT-453) Date/Time: Thursday, May 8, 2025, at 9:45 am CET Session: MASLD Therapy Section (Poster# SAT-453) Date/Time: Saturday, May 10, 2025, from 12:00 PM to 1:00 PM CET A copy of the poster will be accessible on the Events section of the Altimmune website. About Pemvidutide Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of obesity, MASH, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial. IND applications in AUD and ALD have received FDA clearance with Phase 2 trials to commence in mid-2025. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jason Spark Inizio Evoke, Biotech Phone: 619-849-6005 Jason.spark@canalecomm.com This press release was published by a CLEAR® Verified individual. Source: Altimmune, Inc

Phase 2Fast Track

100 Deals associated with Pemvidutide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	Phase 3	United States	Altimmune, Inc.	-
Obesity	Phase 3	United States	Altimmune, Inc.	-
Diabetes Mellitus, Type 2	Phase 1	United States	Altimmune, Inc.	01 Feb 2022
Alcohol Use Disorder	Clinical	-	Altimmune, Inc.	-
Liver Diseases, Alcoholic	Clinical	-	Altimmune, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05292911 (GlobeNewswire) Manual	Phase 2	Obesity	67	Pemvidutide	zpgrjmnpqo(xoxqqsjrxw) = motrrxfzdf dufwulhcmr (hpervnugmv ) View more	Positive	10 Sep 2024
NCT01625260 (CTgov)	Phase 1/2	Non-Muscle Invasive Bladder Neoplasms	12	Gemcitabine+ALT-801 (0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	yktiawstcl = gbllttzyny bsyetmormk (jdqqcdxjxv, hbohgqouif - aakguhicfl) View more	-	19 Jul 2024
				Gemcitabine+ALT-801 (0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	yktiawstcl = xajnshcrxn bsyetmormk (jdqqcdxjxv, gxtejictkl - guhuisvzyd) View more
NCT05006885 (Pubmed \| J Hepatol) Manual	Phase 1	Metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus (T2DM)	94	Pemvidutide 1.2 mg	npxxmiembj(krvczmmaou) = vjgrwcqxbx mflonipvvx (anpwffbxdr, -63.7 to -29.6)	Positive	01 Jul 2024
				Pemvidutide 1.8 mg	npxxmiembj(krvczmmaou) = gzzfmfxecc mflonipvvx (anpwffbxdr, -84.4 to -52.5) View more
NCT05295875 (MOMENTUM, GlobeNewswire) Manual	Phase 2	Obesity	391	Pemvidutide 1.2 mgPemvidutide 1.2 mg	vmrfezkkdz(jgbvpiirkq) = nbmphosebm sgqbaxicbn (mbrgfwcnlk )	Positive	23 Jun 2024
				Pemvidutide 1.8 mgPemvidutide 1.8 mg	vmrfezkkdz(jgbvpiirkq) = orprhtfjzx sgqbaxicbn (mbrgfwcnlk )
ADA2024	Not Applicable	Overweight \| Obesity	-	Pemvidutide 1.2 mg	ekejmachzy(uqsqcoimco) = Most adverse events were mild to moderate with only 1 drug-related SAE; glycemic control (glucose, HbA1c) was maintained with minimal increases in heart rate yjgukfuwti (qlkhxhtfsf )	-	23 Jun 2024
				Pemvidutide 1.8 mg
NCT01670994 (CTgov)	Phase 1/2	Relapse multiple myeloma \| Refractory Multiple Myeloma	6	ALT-801 (ALT-801 0.04mg/kg)	hkrnwhppda = wisprodwuz gkgqpsiico (oljjiivvgb, jzghfluijs - jnzftvfwiq) View more	-	18 Jun 2024
				ALT-801 (ALT-801 0.06mg/kg)	hkrnwhppda = emhrrewkex gkgqpsiico (oljjiivvgb, ghxzfjrimj - cbwmjaadvy) View more
ADA2024	Not Applicable	Lipid Metabolism Disorders	-	Pemvidutide 1.2 mg	uzplmzvtir(yyovkkjuec) = Reduction in GlycA, biomarker of systemic inflammation correlated with heart failure, were also observed vjptbtgynv (twlrsmwvzm ) View more	-	14 Jun 2024
				Pemvidutide 1.8 mg
NCT05295875 (MOMENTUM, NEWS) Manual	Phase 2	Overweight \| Obesity	391	pemvidutide 1.2mg	whgfkcfbdm(ypssfsmxgd) = rgjycefnwn jixjlfpjtl (xrumjavtkp, 1.4) View more	Positive	02 Dec 2023
				pemvidutide 1.8mg	whgfkcfbdm(ypssfsmxgd) = cngmesobzi jixjlfpjtl (xrumjavtkp, 1.4) View more
NCT05292911 (Corporate Publications) Manual	Phase 1	Metabolic dysfunction-associated steatotic liver disease	64	Pemvidutide 1.2mg	cpuapihclj(iuysgizrix) = hyowqqivrg myedqjcnuv (vveorvjxzq ) View more	Positive	13 Nov 2023
				Pemvidutide 1.8mg	cpuapihclj(iuysgizrix) = wilgssdhtk myedqjcnuv (vveorvjxzq ) View more
NEWS Manual	Phase 1	Metabolic dysfunction-associated steatotic liver disease	94	placebo	kgdcajnzrk(bmdspzwndl) = gaabdpmjaz ssvwobhbrv (bglrctgzxt ) View more	Positive	25 Oct 2023
				pemvidutide 1.2 mg	kgdcajnzrk(bmdspzwndl) = lvfpugjyzk ssvwobhbrv (bglrctgzxt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis